We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+30.04%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$647M
AUM Growth
-$1.41M
Cap. Flow
-$89M
Cap. Flow %
-13.75%
Top 10 Hldgs %
48.48%
Holding
76
New
6
Increased
14
Reduced
49
Closed
5

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$17.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.1M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$8.98M
4
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$6.6M
5
HRTX icon
Heron Therapeutics
HRTX
+$6.43M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$33.6M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$31.8M
3
TPST icon
Tempest Therapeutics
TPST
+$12.9M
4
PBYI icon
Puma Biotechnology
PBYI
+$11.3M
5
KITE
Kite Pharma, Inc.
KITE
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Miscellaneous 14.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$64.4M 9.95%
390,312
-251,488
-39% -$31.8M
ALKS icon
2
Alkermes
ALKS
$7.73B
$42.7M 6.6%
700,000
+250,000
+56% +$17.1M
PBYI icon
3
Puma Biotechnology
PBYI
$485M
$39.5M 6.1%
167,300
-52,700
-24% -$11.3M
EGRX
4
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$30M 4.64%
716,500
+316,500
+79% +$8.98M
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$29.6M 4.58%
459,000
+209,000
+84% +$13.1M
NBIX icon
6
Neurocrine Biosciences
NBIX
$15.2B
$28.5M 4.41%
718,900
-281,100
-28% -$10.1M
PTLA
7
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$21.8M 3.37%
574,500
-25,500
-4% -$876K
SRNE
8
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$19.1M 2.95%
1,652,912
-97,088
-6% -$1.12M
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
$19.1M 2.95%
1,138,900
-361,100
-24% -$5.62M
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
$19M 2.94%
27,978
+478
+2% +$302K
HRTX icon
11
Heron Therapeutics
HRTX
$60.3M
$18.5M 2.86%
1,270,000
+570,000
+81% +$6.43M
TPST icon
12
Tempest Therapeutics
TPST
$20M
$16.1M 2.48%
158
-97
-38% -$12.9M
RGLS
13
DELISTED
Regulus Therapeutics
RGLS
$15.2M 2.35%
7,471
-1,696
-19% -$3.69M
ADXS
14
DELISTED
Advaxis Inc
ADXS
$14.1M 2.18%
65,025
+9,058
+16% +$1.39M
ARDX icon
15
Ardelyx
ARDX
$875M
$13.3M 2.05%
1,013,785
-39,715
-4% -$744K
TSRO
16
DELISTED
TESARO, Inc.
TSRO
$11M 1.7%
191,250
-108,750
-36% -$5.12M
KERX
17
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$10.5M 1.62%
826,000
-174,000
-17% -$2.24M
NVAX icon
18
Novavax
NVAX
$1.54B
$10.2M 1.58%
61,915
-13,085
-17% -$2.12M
DXCM icon
19
DexCom
DXCM
$33B
$9.54M 1.47%
612,000
-188,000
-24% -$2.84M
KPTI icon
20
Karyopharm Therapeutics
KPTI
$38.6M
$9.21M 1.42%
20,066
-5,601
-22% -$2.41M
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$9.16M 1.42%
317,475
+67,475
+27% +$1.85M
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
$8.65M 1.34%
229,500
-170,500
-43% -$6.77M
OMER icon
23
Omeros
OMER
$1.26B
$8.56M 1.32%
388,500
-193,800
-33% -$4.42M
EPRS
24
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$8.03M 1.24%
896,600
+821,600
+1,095% +$6.6M
PFNX
25
DELISTED
Pfenex Inc.
PFNX
$7.57M 1.17%
+474,900
New +$5.23M
1
2 3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Cormorant Asset Management held 76 positions worth $647M, down 0.22% from $649M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management withdrew a net $89M in Q1 2015, closing 5 positions and reducing 49 holdings. Its most notable exit was Celgene Corp, an estimated $33.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 81% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Epizyme, Inc worth $5M.

  • Cormorant Asset Management's largest Q1 2015 buy was Epizyme, Inc: 266,250 shares worth $5M.
  • Cormorant Asset Management added most to Alkermes in Q1 2015, an estimated $17.1M increase.
  • Cormorant Asset Management's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $31.8M.
  • Cormorant Asset Management fully exited Celgene Corp in Q1 2015, selling an estimated $33.6M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $647M portfolio in Q1 2015.
  • Cormorant Asset Management opened 6 new positions and closed 5 in Q1 2015.
  • Cormorant Asset Management's portfolio value fell 0.22% quarter-over-quarter to $647M.

Based on Cormorant Asset Management's 13F filing for Q1 2015, filed 15 May 2015.